- Save article
Industry newsWHO Pandemic Agreement gains signatories
The President of UNITE signs statement in support of the World Health Organization (WHO) Pandemic Agreement
- Save article
Industry newsWHO issues warning on fake opioids in Europe
The World Health Organization (WHO) has issued an alert that falsified Oxymorphone Hydrochloride has been detected in Finland.
- Save article
Industry newsCholera vaccine shortage puts millions at risk
The World Health Organization has declared a worldwide shortage of the oral cholera vaccine amid an upsurge in cases.
- Save article
JournalUnique aspects of biologic reference standards
Reference standards are pivotal in ensuring pharmaceutical quality, especially for complex biologics. This article reviews definitions and classifications of reference standards as outlined by the US Food and Drug Administration (FDA), the World Health Organization (WHO) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q6B and Q7 guidelines. It addresses types of standards based on source and use, with particular emphasis on the distinct requirements for biologics.
- Save article
Industry newsWHO endorses use of R21/Matrix-M malaria vaccine in children
The World Health Organization (WHO) has recommended widespread use of the R21/Matrix-M malaria vaccine in children.
- Save article
EditorialThe global access battle for healthcare equity
Regulatory Rapporteur June 2024 | Volume 21 | No.6 The World Health Organization (WHO) has estimated that one-third of the global population lacks regular access to essential medicines. The concept of access to medicines will likely resonate differently within ...
- Save article
JournalThe use of prior knowledge and platform approaches in early vaccine development
This article explores how platform approaches and prior knowledge can be used in the early development of vaccines.
- Save article
JournalMD4/IVD4: Bridging the gaps – Developments in medical device and IVD regulatory harmonisation
This is a report of the MD4/IVD4 session that took place at this year’s Symposium.
- Save article
JournalPS1: Tailored development of biosimilars without efficacy and safety studies – Is this the future?
This is a report of the PS1 session that took place at this year’s Symposium.
- Save article
JournalTarget product profile and product profile characteristics for labelling during drug development
This article analyses the role of the TPP and PPC in labelling development and uses case studies as examples.
Search results
The Organisation for Professionals in Regulatory Affairs
- Contact us
- Copyright © 2015-2025 The Organisation for Professionals in Regulatory Affairs Ltd. t/a Regulatory Rapporteur - All rights reserved